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Abstract 
Anaphase-promoting complex/cyclosome (APC/C) is a multifunctional ubiquitin-protein ligase that targets different 
substrates for ubiquitylation and therefore regulates a variety of cellular processes such as cell division, differentiation, 
genome stability, energy metabolism, cell death, autophagy as well as carcinogenesis. Activity of APC/C is principally 
governed by two WD-40 domain proteins, Cdc20 and Cdh1, in and beyond cell cycle. In the past decade, the results 
based on numerous biochemical, 3D structural, mouse genetic and small molecule inhibitor studies have largely 
attracted our attention into the emerging role of APC/C and its regulation in biological function, human diseases and 
potential therapeutics. This review will aim to summarize some recently reported insights into APC/C in regulating 
cellular function, connection of its dysfunction with human diseases and its implication of therapeutics.
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Background
The ubiquitin–proteasome system (UPS) plays a critical 
role in regulating numerous cellular pathways through 
controlling the abundance, activity and localization of an 
enormous variety of cellular proteins [1]. Overall, three 
essential enzymes, E1, E2, and E3, the activating, conju-
gating, and ligase enzymes respectively that methodically 
relocate Ubiquitin molecules [2]. The ubiquitin chain 
attached substrate protein will be then either recognized 
by the proteasome for destruction or undergo for modi-
fication [3–5]. Specifically, the E3 ligase can be classified 
into the HECT (homologous to the E6-AP carboxyl ter-
minus) domain containing E3s and the Really Interesting 
New Gene (RING) domain containing E3s [6].
It is thought that HECT E3s usually catalyze the forma-
tion covalent bonds between cysteine residues of ubiqui-
tin molecules before transferring the ubiquitin molecule 
to the protein, whereas RING E3s catalyze the transfer of 
the ubiquitin from the E2 to the substrate protein [5]. The 
modification of substrate protein by ubiquitin molecule 
could be through mono-ubiquitylation or various types 
of poly-ubiquitylation [2]. It has been demonstrated that 
seven individual lysine residues on the ubiquitin mol-
ecule, including K6, K11, K27, K29, K33, K48 and K63, 
could form different types of ubiquitin chain attaching to 
the substrate protein in order to achieve various physio-
logical regulation [7–9]. Results from the human genome 
sequencing indicated the presence of approximately 600 
different ubiquitin ligases [5]. Among these E3 ligases, 
the Skp1–Cullin-1–F-box protein (SCF) and APC/C, 
are two well studied RING finger type E3 ligases, which 
provide us good example to dissect other new E3 ligases 
[5, 10, 11]. This review will focus on some relatively new 
aspects of APC/C reported in recent years in cell cycle 
control, apoptosis, energy metabolism, autophagy, and 
carcinogenesis and drug development.
Architecture of APC/C
In comparison with SCF complex, APC appears to be 
more sophisticated in term of its architecture due to the 
feature of its large complex [10–12]. The APC/C is a 1.5 
megadaltons assembly ubiquitin ligase complex com-
prising 19 subunits [13, 14]. It takes relatively long to 
biochemically dissect and recapitulate this multiple-sub-
unit enzyme. Now it is clear, in vertebrates, the APC/C 
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holoenzyme is a complex of 15 different proteins includ-
ing ANAPC1/APC1/TSG24, ANAPC2/APC2, ANAPC3/ 
APC3/Cdc27, ANAPC4/APC4, ANAPC5/APC5, ANAP-
C6/APC6/Cdc6, ANAPC7/APC7, ANAPC8/APC8/Cd- 
c23, ANAPC10/APC10/Doc1, ANAPC11/APC11, ANA-
PC12/APC12/CDC26, ANAPC14/APC13/SWM1, ANA-
PC15/APC15/Mnd2, ANAPC16/APC16, as well as the 
co-activator subunit (Cdc20 or Cdh1) [13, 15, 16]. The 
schematic representation of the conserved domain of 
these subunits was shown in Fig. 1a.
Comprehensive studies with structural, genetic and 
biochemical approaches have sketched the general archi-
tecture and revealed the underlying mechanism by which 
APC/C recognizes, and catalyzes ubiquitination of the tar-
geting proteins [13, 16–18]. Overall, the APC/C complex 
consists of three sub-complexes: the scaffolding subcom-
plex platform, the catalytic and substrate identification 
core and a tetratricopeptide repeat (TPR) arm (Fig.  1b). 
The scaffolding sub-complex is composed of APC1/
TSG24, APC4 and APC5; the catalytic sub-complex con-
tains APC2, APC10 and RING finger protein APC11; 
and the TPR arm consisting of APC3, APC6, APC7 and 
APC8, which provides binding sites for the scaffolding 
subunit and one of the coactivators (Cdc20 or Cdh1). On 
the platform, the APC1 subunit is the bridge between the 
catalytic portion and the TPR arm. APC3, in the catalytic 
sub-complex acts as a platform for the catalytic core. In 
turn, APC11 regulates the interface with E2 enzymes. It is 
also worth noting that APC10 forms a majority of where 
the substrate binds. The APC10 might also contribute to 
substrate recruitment via its degron-recognition module 
[16]. The TPR arm functions as the important scaffold-
ing to the APC/C. In addition to APC3, APC6, APC7 and 
APC8 in the TPR arm, other factors including APC12, 
APC13, and APC16 may also play a role in stabilizing 
the TPR arm. APC12, APC8, APC7, APC6 and APC3 are 
present as dimers, other subunits exist as monomers. The 
TPR motifs of APC3 recruit Cdc20 or Cdh1 via binding 
to homologous carboxyl (C)-terminal Ile-Arg sequences 
displayed at APC10 and Cdc20 or Cdh1. Interestingly, the 
Barford group has recently demonstrated atomic struc-
tures of APC/C–coactivator complexes with either an 
UbcH10–ubiquitin conjugate or Emi1 via cryo-electron 
microscopy. By analysis of these structures, it was shown 
how Emi1 antagonizes the two E2s, UbcH10 and Ube2S 
and details of the initiating sequential ubiquitination 
reaction [13]. While our understanding of APC/C for its 
enzymology and 3D architecture has been tremendously 
expanded, some important knowledge about APC is still 
missing, for instance, the assembly mechanism of APC/C 
under various cellular conditions and if all 15 subunits are 
necessary for APC/C acting under different physiological 
circumstances.
Mechanisms of ubiquitin chain formation by the 
APC/C
Polyubiquitination by E1, E2, and E3 enzyme cascade 
is a principal mechanism modifying protein function. 
APC complex catalyzes polyubiquitination by two-step 
sequential reactions with two different E2s [19]. In stud-
ies done in S. cerevisiae, it was shown that the APC/C 
generates lysine 48 (K48)-linked chains and that two dif-
ferent E2s, Ubc4 and Ubc1, regulate the extension [17]. 
The initial modification of K48 is accomplished by Ubc4 
and Ubc1 is responsible for chain elongation [20]. Mak-
ing of K48-connected chains requires residues situated in 
two loops in the region of the active site cysteine of Ubc1 
[21]. Ubc4 and Ubc1 having the conserved scaffold have 
developed distinctive mechanisms to perform the same 
work that generating K48-linked poly-Ubiquitin chains. 
In human, the “initiating” E2s, UBCH10 or UBCH5 
(homolog of S. cerevisiae Ubc4, including UbcH5a and 
UbcH5c), with APC/C complex ligates ubiquitin to 
Cdc20 or Cdh1-bound substrate. The “elongating” E2 
UBE2S extends a poly-Ub chain on the Ub-prepared 
substrate. UbcH5a and UbcH5c can utilize ubi-K11, 
ubi-K48, and ubi-K63 to catalyze the ubiquitination of 
APC/C–Cdh1-substrates, however, UbcH10 only cata-
lyzes chains linked via K11, which is different in S. cerevi-
siae [22] (Fig. 2).
In recent studies in humans, there were two E2 
enzymes identified, UBCH10 and UBE2S that were found 
to be crucial regulators of cell division and identified 
as potential signalers for the degradation of APC/C. It 
was also found in recent studies that chains of K11 are 
increasingly upregulated in mitotically active cells where 
substrates of APC/C are degraded [23]. It was shown that 
linkages of K11 by the E2, UBE2S, promotes the degra-
dation of APC/C substrates independently of K48 chains 
[24]. K11 chains which triggering degradation of a variety 
of cell cycle regulators during mitosis are dispensable for 
most APC/C substrates [4].
Recently studies revealed how E2 enzymes UBCH10 
and UBE2S control K11 chain initiating and elongating. 
Firstly UBCH10 an E2 enzyme is recruited to APC/C 
and subsequently stimulated for ubiquitination. It is then 
situated for substrate targeting via complexing with the 
APC cullin-RING core and interactions with APC2. An 
interaction between the UBC domain and the Apc11 
RING surface activates UbcH10, which subsequently 
triggers an E2-ubiquitin intermediary for substrate alter-
ation. By means of KEN- and D-box binding to Cdh1 and 
the APC core, the E3 primed substrate is co-recruited 
at a separation. The APC/C–Cdh1–UBCH10∼Ub–sub-
strate complex intermediately ligates Ub directly to an E3 
primed substrate [25]. Since UbcH10 and Apc11-RING 
communicate via a classic E2-RING interface, the APC/C 
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Fig. 1 Structure and genetics characteristics of APC/C. a Graphic representation of human (Homo sapiens) APC/C subunits. All domains are signi-
fied by colored boxes and full length protein sequences are shown by gray lines. b A schematic illustration of the structure organization of APC/C 
complex. APC/C complex contains three sub-complexes: the scaffolding platform, the TPR lobe and the catalytic core. The scaffolding platform 
consists of APC1, APC4 and APC5. The catalytic core consists of APC2 (Cullin family related protein), APC10, APC11 (RING finger protein), Cdc20 or 
Cdh1 (catalytic coactivators) and substrate. The TPR lobe consists of APC3, APC6, APC8, APC7, APC13, APC16, and Cdc26. The scaffolding platform 
connects the TPR lobe to the catalytic core
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has been shown to stimulate the innate catalytic activity 
of UbcH10–ubiquitin by fortifying a closed conformation 
state that resulting the lysine on the substrate attacking 
the E2-ubiquitin thioester bond and transferring of ubiq-
uitin. Subsequently, there is poly-Ub chain elongation 
in which ubiquitin of the current chain capacities as the 
acceptor as well as the substrate. Cdc20 or Cdh1, recog-
nizes UBE2S by means of its particular C-terminal locale 
and exchanges the ubiquitin to APC/C. In this reaction, 
APC/C determines the binding location for both accep-
tor ubiquitin and the E2 (UBE2S) enzyme, whereas the 
RING domain of APC11, which is required to position 
the acceptor ubiquitin, seems to be responsible for accep-
tor recognition [19, 26]. It has also been shown that dur-
ing the creation of the chain, the discrete APC11 RING 
surface aids in delivering the Ubiquitin primed substrate 
to accept an additional ubiquitin from UBE2S. There-
fore, UBCH10 and UBE2S have comparable affinities to 
APC/C. The sequential binding of UBCH10 and UBE2S 
are caused by binding to distinct sites on the complex. 
Thus, APC/C and specific adaptor proteins need to dis-
tinguish different substrates as well as ubiquitin mol-
ecules for the first ubiquitylation. For subsequent chain 
elongation, both ubiquitin-charged UbcH5/UbcH10 and 
UBE2S are required (Fig. 2).
The APC/C inhibitor protein early mitotic inhibitor 1 
(Emi1) antagonizes the function of UbcH10 and UBE2S, 
which are accountable for catalyzing chain origination 
and elongation, correspondingly [13]. The mechanism 
of action of Emi1 is that the zinc-binding region (ZBR) 
identifies D-box motifs on the different substrate and 
subsequently inhibits the UbcH10-dependent APC/C 
activity. The architecture of ZBR motif named in-
between-RING (IBR) associated with Apc2–Apc11 and 
the linker between Emi1 D box and ZBR motif shapes 
an α-helix that complexes against the Emi1-ZBR β-sheet 
and docks onto the site on Apc11-RING where UbcH10 
binding. It is worth noting that the Emi1 ZBR motif does 
not inhibit the UBE2S-catalyzed ubiquitination reactions 
[27, 28]. The C-terminal LRRL motif of Emil1 is indistin-
guishable to the LRRL motif on UBE2S, which is required 
for APC/C–UBE2S binding. Thus, the Emil1 antagonizes 
UBE2S binds to APC/C via LRRL motif and inhibits 
APC/C activity.
Regulations of APC/C
It has been demonstrated that regulation of APC turns to 
be sophisticated by various mechanisms such as substrate 
specific factors and different types of posttranslational 
modifications, including phosphorylation, sumoylation and 
acetylation [12, 29–31]. Principally, the activation of APC/C 
is governed by two WD-40 family proteins Cdh1 or Cdc20 
[12]. Despite these two substrate factors, the on/off of APC 
during the cell cycle progression is also determined by phos-
phorylation, the mitotic checkpoint complex (MCC) and 
interphase early mitotic inhibitor 1 (Emi1) (Fig. 3).
Fig. 2 Mechanisms of Ubiquitin chain formation by the APC/C. The APC/C catalytic polyubiquitination chain formation by two-step sequential 
reactions with two E2s: initiating E2 (E2i) and elongating E2 (E2e). In homo sapiens, the “initiating” E2s, UBCH5 or UBCH10, with APC/C complex 
ligates ubiquitin to substrate and the “elongating” E2 UBE2S expands a K11 polyubiquitination chain on the Ubiquitin-primed substrate. The UBCH5 
or UBCH10 binds to APC11 to initiate substrate ubiquitinated, then the UBE2S is recruited to the APC/C by Cdh1/Cdc20. In the chain elongating 
assembly, the APC/C binding site and the non-canonical distinct APC11 RING surface helps UBE2S deliver K11 polyubiquitination chain to the sub-
strate. In S. cerevisiae, the “initiating” E2, Ubc4 and the “elongating” E2 Ubc1 deliver a K48 polyubiquitination chain to the substrate
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Activation of APC/C by Cdc20 or Cdh1 has been thor-
oughly studied in the past 20  years. C termini on both 
Cdc20 and Cdh1 include a WD40 domain that attracts 
different APC/C substrates along with promoting ubiq-
uitylation via augmenting the interaction of APC/C and 
UbcH10 and UBE2S (Fig. 1a) [32]. It is also proposed that 
Cdc20 and Cdh1 bind to different regions of APC8 and 
APC3 via interactions with the TPR motifs (Fig. 1b) [32]. 
Despite Cdc20 and Cdh1 have the similar structures, they 
activate the APC/C at distinctive periods. Cdc20 associ-
ates with APC/C in early mitosis which is followed by the 
destruction of different substrates involved in mitosis. 
Subsequently, Cdh1 replaces Cdc20 amid anaphase and 
also extending into the G1 phase. CDK1 subsequently 
phosphorylates Cdh1, which then has the effect of inhib-
iting its interaction with APC/C until later in anaphase. 
The diminishing CDK1 activity coupled with expanded 
phosphatase activity is subsequently followed by Cdh1 
dephosphorylation, which then ties to and initiates the 
APC/C activity, in this way bringing on substrate degra-
dation in late mitosis and during G1 phase.
Cdc20 and Cdh1 are well-established substrate recep-
tors for APC/C. Recently study showed that these two 
adaptors can also target cell cycle proteins for destruc-
tion through a second ubiquitin ligase, Parkin [33]. Par-
kin networks with the APC/C coactivators Cdc20 and 
Cdh1, which is independent of the APC/C–Cdh1/Cdc20 
complex to degrade some key mitotic controllers such 
as Cyclin B1, Aurora-B. Parkin insufficiency leads to its 
substrates aberrant expression, mitotic imperfections, 
genome instability as well as tumorigenesis. Cdh1 and 
Cdc20 both could be acetylated and their hyperacetyla-
tion inhibits the APC/C activity. The sirtuin family mem-
ber SIRT2 could catalyze Cdh1 and Cdc20 deacetylation 
to maintain normal mitosis. SIRT2 deficiency also leads 
to mitotic defects, genome instability, as well as tumori-
genesis [34].
The mitotic checkpoint complex (MCC), which con-
tains spindle assembly checkpoint (SAC) proteins includ-
ing MAD2/MAD3 (mitotic arrest deficient), BUB3 
(budding uninhibited by benzimidazole), and Cdc20, pre-
vents immature anaphase onset through APC/C activ-
ity inhibition [35]. The inhibition regulation of APC/C 
activity by MCC is fundamental for the SAC. The MCC 
components have the action of inhibiting the attraction 
of different mitotic intermediates, such as cyclin B and 
securin, which require recognition via KEN-box and 
D-box motifs, and consequently restrain APC/C robustly 
ubiquitinates diverse substrates. The MCC is able to 
inhibit an additional Cdc20 that has previously interacted 
with APC/C, which has the action of preventing ana-
phase step in the absence of kinetochore signaling [36]. 
Bub3 kinetochore localization is needed for the correct 
time signaling of anaphase commencement and for usual 
associated with APC/C and Cdc20 [37]. The BUBR1 acti-
vation regulated by Bub3 has two distinct roles: in unat-
tached kinetochores, Bub3 enhances signaling to form 
BubR1 and Cdc20 complex via inherent binding sites 
downstream of kinetochore-produced complexes, thus 
promoting two specific BubR1-Cdc20 binding interac-
tions. Cdc20–Mad2 binding lead to exposing the bind-
ing site of Cdc20 for BubR1 binding via its N-terminal 
conserved Cdc20 binding domain, whereas the Bub3 
promotes Cdc20-BubR1 binding [38]. Recently studies 
demonstrated that Bub3–BubR1-dependent appropria-
tion of Cdc20 at DNA breaks could facilitate proper seg-
regation of broken chromosomes [39].
Early mitotic inhibitor 1 (Emi1) has a significant role 
during interphase of the cell cycle to constrain APC/C 
activity, which is the subsequent consequence of increas-
ing the levels of mitotic cyclins for entry into mitosis. 
Emi1 contains a Zn-Binding Region (ZBR) and a con-
served D-box, both of which contribute to the inhibi-
tion of APC/C activity through binding to the APC/C 
core complex and its coactivators Cdc20 or Cdh1. Emi1 
binds APC/C coactivators via its D-box with high affin-
ity, preventing the recruitment of APC/C substrates to 
the APC/C core complex, while the ZBR domain directly 
suppresses APC/C E3 ligase activity by associating with 
the APC/C core subunits. In this scenario, Emi1 func-
tions as an APC/C “pseudo-substrate” to block APC/C’s 
access to other substrates [40]. Phosphorylation by Plk1 
Fig. 3 Regulation of APC/C activity. The APC/C activity is governed 
by catalytic coactivators Cdh1/Cdc20, mitotic checkpoint complex 
(MCC) and Emi1/2. The MCC complex including MAD2/MAD3, BUB3, 
BubR1 and Cdc20 generates an inhibitor of APC/C activity to prevent 
premature anaphase onset. The MCC is able to inhibit both unli-
ganded Cdc20 and Cdc20 bound to the APC/C. Emi1 functions as an 
APC/C “pseudo-substrate” to block APC/C’s access to other substrates, 
whereas Emi2 inhibits APC/C by targeting its association with the 
coactivator Cdc20. The posttranslational modifications, including 
phosphorylation, could modulate APC/C activity. The large tumor 
suppressor kinase 1 and 2 (LATS1/LATS2) phosphorylate APC12/
CDC26 to modulate TPR lobe assembly and APC/C activity
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and ubiquitination by SCF/β-TrCP (β-transducin repeat-
containing protein) at the onset of mitosis leads to Emi1 
degradation, which resulting APC/C activation. In addi-
tion to Emi1, Emi2 likewise hinders APC/C activity by 
competitively inhibiting association of E2 Ube2S with 
APC10 subunit of the APC/C [41].
Phosphorylation regulation the subunits of APC/C 
is crucial for APC/C activity modulation. Recent study 
revealed several novel phosphorylation regulation the 
subunits of APC/C. The large tumor suppressor kinase 
1 and 2 (LATS1/LATS2) are serine/threonine kinases 
of the AGC kinase family and core components of the 
Hippo pathway in mammals. APC12/CDC26 is phospho-
rylated by LATS 1 and LATS2 to modify the interactions 
of the tetratricopeptide repeat subcomplex of APC/C and 
to subsequently regulate its activity [42].
During mitosis, there have been studies that show reg-
ulating translation of proteins rather than transcription 
of mRNA that is the most significant mechanism regulat-
ing protein expression during mitosis. One of the most 
pronounced translationally-repressed genes is Emi1 [43]. 
The translational repression of Emi1 is required for full 
APC activation. Therefore, gene-specific translational 
repression may complement post-translational mecha-
nisms for regulating APC/C activity.
The deubiquitinases (DUBs) are apparatuses of the 
ubiquitin proteasome system that catalyze the elimina-
tion of ubiquitin molecules from proteins causing dis-
torted signaling in protein stability [44, 45]. Nearly 100 
DUBs are encoded by the human genome to work in 
concert with E3 ligases [46]. Several deubiquitinases have 
been reported to counteract APC/C. Ubiquitin-specific 
protease 44 (USP44) works by deubiquitinating Cdc20 
and promote the MAD2-Cdc20 complex stabilization 
[47]. During cell cycle, deubiquitinase USP37 protein and 
activity are fluctuated: in G1 phase, the E2F transcrip-
tion factors trigger its expression; and then its protein 
levels accumulated in G1/S; following phosphorylated by 
CDK2, its activity reach to peak; finally its protein was 
degraded in late mitosis. In G1/S, Activated USP37 binds 
to Cdh1 and deubiquitinates cyclin A, which Promote S 
Phase Entry [48]. Deubiquitinase USP22 is a substrate of 
APC/C–Cdc20 during cell exit from M phase. USP22 is 
activated by CDK1 phosphorylation and deubiquitinates 
and stabilizes Cyclin B1 to promote cell cycle progres-
sion [49]. In budding yeast, the deubiquitinase Ubp15 
associates Cdh1 and S-phase cyclin gene Clb5. Clb5 is 
proteolyzed by APC/C and is deubiquitinated by Ubp15. 
Accumulated Clb5 by Ubp15 deubiquitinating activity is 
critical for timely entry into S phase [50]. Therefore, the 
tango between APC and deubiquitinase contributes to 
the generation of the switch-like transition controlling 
cell cycle progression [51].
APC/C in cell cycle regulation
The impact of the APC/C function was initially impli-
cated in the regulation of cell cycle progression, although 
now it is well known for its multifunctional role in the 
regulation of genomic stability, apoptosis, metabolism 
and development through degradation of specific func-
tional proteins. Regulation of cell cycle advancement 
by the APC/C occurs primarily through the tempo-
ral coordination of two co-activators, Cdc20 or Cdh1, 
which form either the APC/C–Cdc20 or APC/C–Cdh1 
E3 ligase complex. Although APC/C–Cdc20 or APC/C–
Cdh1 have some substrates overlap, APC/C–Cdc20 pri-
marily controls the metaphase to anaphase shift and 
mitotic exit, while APC/C–Cdh1 is primarily active dur-
ing the end of mitotic exit and early G1 phase (Fig. 4).
Cdc20 but not Cdh1 plays an important role in regu-
lating G2 progression. During G2 phase, Cdc20 is phos-
phorylated by Cdk1 and other mitotic kinases, which 
activates APC/C–Cdc20 in part by promoting the inter-
action between Cdc20 and the APC/C core complex [52, 
53]. The SAC activates and sequester Cdc20 from the 
APC/C core complex by the mitotic checkpoint complex 
(MCC) when occurring aberrant mitotic events, such as 
misaligned spindles or improperly attached kinetochores 
on sister chromatids. When the checkpoint requirement 
is satisfied after all sister chromatids are connected to the 
bipolar spindle, the inhibition towards APC/C–Cdc20 is 
diminished. APC/C–Cdc20 degrades NEK2A and cyc-
lin A in prometaphase [54] and securin and cyclin B1 in 
metaphase. APC/C–Cdc20 complex binds to Cyclin B1 
and commences its destruction when chromosome bi-
orientation, which dependent on the spindle checkpoint. 
Recently studies revealed that MASTL is crucial for the 
recruitment of cyclin B1 to the APC/C, without the need 
of Cdc20, which subsequently results in CyclinB1 degra-
dation once the checkpoint has been lifted [55, 56]. The 
ubiquitination and destruction of Securin, which is an 
inhibitor of Separase, led Separase to cleave the cohesin 
complexes and subsequently trigger sister chromatid seg-
regation [57]. During metaphase, the spindle checkpoint 
is silenced and Cdk1 activity is minimized, which even-
tually gives a “GO” signal for anaphase to commence. In 
adverse to early-destroyed cyclins such as Cyclins A and 
B1, which restrain APC/C function, the distinct member 
of cyclin B family member, Cyclin B3 is a mitotic cyclin 
stimulates APC/C activity and promotes the metaphase–
anaphase transition [58].
It is thought that Cdh1 maintains in silence from G2 
and early mitosis due to its phosphorylation [30, 52]. At 
mitotic exit, including anaphase and telophase, dephos-
phorylation of Cdh1 by CDC14 [59], APC/C–Cdh1 is 
activated and ubiquitylates Cdc20 [60], Aurora kinases 
(Aurora A and B) [61, 62], Tpx2 [63] and Polo-like kinase 
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1 (PLK1) [64] which ensures a low kinase activity envi-
ronment to pave the road for mitotic exit. Interestingly, 
it was recently reported that the APC/C regulates spin-
dle formation through promoting the degradation of 
four spindle-binding proteins Bard1, Hmmr, HURP and 
NuSAP [65]. Furthermore, the stress-activated kinase 
JNK [66], HEC1 [67] and EYA1 [68] were also identi-
fied to be ubiquitin substrates of APC/C–Cdh1 during 
the transition from mitosis to the G1 phase. During G1 
phase, APC/C–Cdh1 destructs mitotic cyclins, Cdc25A 
[69], Skp2 [70], Ndd1 [71], USP37 [48] and Cks1 [70] to 
sustain low Cdk activity. In addition, APC/C–Cdh1 regu-
lates the destruction of replication regulators including 
Geminin [72] and Cdc6 [73], RRM2 [74], Claspin [75] as 
well as its own E2, Ube2C and UbcH10 [76, 77], which 
leads to inactivation of APC/C–Cdh1 and resulting sta-
bilization of Cyclin A. While APC/C–Cdh1 destructs 
substrates during G1 phase specifically, these substrates 
are degraded via SCF ligases in other phase of the cell 
cycle. For examples, the substrates Cdc25A [78], Claspin 
[79], and USP37 [80] are destructed by SCFβ-TrCP in S and 
G2 phase; the substrate RRM2 is degraded via SCFCyclin 
F [81]. During G1–S transition, APC/C–Cdh1 is deacti-
vated via two mechanisms: binding to Emi1 and degra-
dation of UbcH10, UBE2C [76, 77]. During normal S 
and G2 phase, Cyclin A/Cdk2 binds and phosphorylates 
Cdh1 to uphold the APC/C in its deactivated state [82].
Despite the master regulatory role in regulating cell 
cycle, accumulating evidence uncover the impact of 
APC/C in an assortment of cellular processes beyond cell 
Fig. 4 APC/C in cell cycle regulation. The regulation of APC/C activity and the order degradation of APC/C substrates during cell cycle progression. 
Regulation of cell cycle progression by the APC/C occurs primarily through the temporal coordination of Cdc20 or Cdh1. APC/C–Cdc20 degrades 
substrates in early and mid-mitosis, while APC/C–Cdh1 degrades substrates after anaphase commencement, during the end of mitosis and G1 
phase. During G2/M transition phase, APC/C–Cdc20 is activated by CDK1 phosphorylation, whereas is inhibited by spindle assembly checkpoint 
(SAC) and mitotic checkpoint complex (MCC). When checkpoint requirement is satisfied, APC/C–Cdc20 ubiquitylates Cyclin-A, NEK2A in prometa-
phase and securin and cyclin B1 in metaphase. When cell commences to anaphase, Cdh1 is dephosphorylated by CDC14 and activates APC/C–
Cdh1. During anaphase and telophase, APC/C–Cdh1 ubiquitylates substrates including Cdc20, Aurora kinases, PLK1, TPX2, spindle-binding proteins 
and stress-activated kinases. During G1 phase, APC/C–Cdh1 degrades mitotic cyclins such as Cdc25A, Skp2. During G1/S transition and G2 phase, 
APC/C–Cdh1 is inactivated by Emi1, Cdh1 degradation, phosphorylation by Cyclin A/Cdk2 and degradation of E2s
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cycle, including regulation of cell differentiation, genomic 
integrity, developmental processes and the nervous sys-
tem (Fig.  5) [83, 84]. Many regulators of DNA damage 
repair and genomic stability such as CtIP [85], Claspin 
[86], UPS1 [87] and Rad17 [84] were recently character-
ized as bona fide Cdh1 substrates. Furthermore, the iden-
tification of Mcl-1 [88] and Bim [89] as a Cdc20 substrate 
as well as G9a and GLP [90] as Cdh1 substrates expands 
APC/C functionality into regulating cellular apoptosis 
and senescence. In addition, APC/C also participates in 
other cell cycle-independent functions including regu-
lating cellular metabolism, cell mobility and gene tran-
scription through degradation of specific substrates. 
Nevertheless, how APC/C–Cdh1 and APC/C–Cdc20 are 
regulated and recruited by various physiological signal-
ing remains not very clear. Given involvement of multi-
ple types of protein posttranslational modifications in 
response to signaling, if crosstalk between APC/C with 
other types of modifications in governing signaling mod-
ule needs to be further studied.
APC/C in genome stability
The major function of APC/C in regulating mitosis and 
meiosis is through dictating temporal chromatid segre-
gation that ensures the fidelity of daughter genome. The 
segregation errors due to malfunction of APC/C activ-
ity leads to chromosomal instability (CIN) with deleteri-
ous consequences. Recently, genetic mouse model works 
specified the loss of Cdh1 related to centrosome amplifi-
cation, chromosome missegregation, thus causing tumor-
igenesis [91]. Loss of the Cdh1 deacetylase SIRT2 leads to 
APC/C activity decrease and subsequential mitotic catas-
trophe, genetic instability, and tumorigenesis [34]. MCC 
complex member BubR1 [92], Bub3 [93, 94], Bub1 [95], 
MAD2 [96] haploinsufficiency causes APC/C–Cdc20 
abnormal activated and lead to premature anaphase and 
loss of chromosome integrity in mammalian cells Moreo-
ver, overexpression of Bub1 [95], Mad2 [97] in transgenic 
mice have the consequences of broken chromosomes, 
anaphase bridges, chromosome gains and deletions, 
and increased rate of tumorigenesis. On the contrary, 
increased expression of BubR1 in transgenic mice seems 
to have a protective effect against aneuploidy and cancer 
[98]. Therefore, APC/C is critical for genomic integrity by 
regulating high fidelity mitosis, abnormal APC/C activity 
leads to genomic instability.
In recent year there has been considerable work to elu-
cidate the mechanism of APC/C–Cdh1 and how it is able 
to control the DNA damage checkpoint response and 
DNA repair via degradation of substrates such as CtIP 
[85], Claspin [86], UPS1 [87] and Rad17 [84]. In response 
to DNA damage, APC/C–Cdh1 is activated by dephos-
phorylation by nucleolus–nucleoplasm translocated 
CDC14B as well as p53- and p21-dependent CDK1 
inactivation and Emi1 downregulation [75, 99]. The 
APC/C–Cdh1 complex seems to regulate the DNA dam-
age-induced G2/M cell cycle checkpoint. While PLK1 
[75], MEF2C [100], FoxM1 [101], Wip1 phosphatase 
[102] are destructed by activated APC/C–Cdh1, other 
substrates like Claspin, 53BP1, Chk2 [103, 104] are pro-
tected. The APC/C–Cdh1 has also been involved in mod-
erating DNA repair. After DNA repair, the DNA damage 
response and DNA repair machinery need to be shut 
down. In the DNA damage response as well as during 
exit from mitosis, CtIP was down-regulated by APC/C–
Cdh1 [85]. Also during mitotic exit, the Rap80 complexes 
with BRCA1 to facilitate homologous recombination, and 
it is then subsequently degraded by APC/C-which seems 
to prevent non-regulated recombination during G1 [105]. 
Thus, it is well-known that correct activation of APC/C–
Cdh1 is needed for robust DNA repair mechanisms, 
which has been shown with studies down in Cdc14B 
knockout cells in which its loss leads to no activation of 
APC/C–Cdh1 thus infective DNA repair [106].
The APC/C–Cdh1 has also been shown to regulate 
cellular replication in studies involving the deubiquit-
inating enzyme USP1 in which it was ubiquitinated and 
degraded by APC/C–Cdh1 allowing PCNA to be mono-
ubiquitinated in response to UV [87]. It has been well 
known that the ATR–Rad17 cascade in which Rad9–
Rad1–Hus1 is loaded on DNA with subsequent activa-
tion of Claspin/Chk1 is needed to activate cell cycle 
checkpoint [107]. UV exposure has also been shown 
to degrade Rad17 via APC/C–Cdh1, which seems to 
be required for entry back into the cell cycle [84]. The 
decrease of Cdh1 lead to Rad17 accumulation and tum-
origenesis, which consistent with the Cdh1 deficiency 
mouse model [108].
APC/C in apoptosis and senescence
Coordination between survival and death after cel-
lular challenge from stress such as radiation shock or 
the treatment with chemotherapeutic drug determines 
the cellular fate. Recent studies implicate the impact 
of APC/C in apoptosis regulation. The APC/C–Cdc20 
destructs anti-apoptotic Mcl-1 [88] and pro-apoptotic 
protein Bim [89]. CDK1/cyclin B1 phosphorylates Mcl-1 
at two specific residues, Thr92 and Ser64. Phosphoryla-
tion of Thr92 starts Mcl-1 ubiquitination and degrada-
tion when cells stopped in mitosis. Therefore, Thr92 
phosphorylation of Mcl-1 by CDK1 and its ubiquitina-
tion and degradation by APC/C–Cdc20 are implicated in 
the beginning of apoptosis in the event that a cell fails to 
undertake mitosis. Bim, a powerful pro-apoptotic factor, 
is also a substrate of APC/C–Cdc20. When prolonged 
inhibition of APC/C–Cdc20 using drugs that stabilize 
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or depolymerize microtubules (Taxol and Nocodazole, 
respectively) induce mitotic arrest and Bim stabilization, 
which leads to cell apoptosis. Another pro-apoptotic 
Bcl-2 family members Bax is regulated by APC/C–Cdh1 
mediated modulator of apoptosis protein 1 (MOAP-
1) degradation [109, 110]. MOAP-1 is a Bax activation 
enhancer induced by DNA damage. APC/C–Cdh1-medi-
ated MOAP-1 degradation is reversed by the ubiquitin 
ligase Trim39. The correlation between mitotic APC/C 
with apoptosis implicates the APC/C complex in being 
able to distinguish between normal events of mitosis and 
those that are prolonged events of mitotic arrest.
Fig. 5 APC/C in genomic integrity, apoptosis, autophagy, senescence, metabolism, stem cell and neuron regulation. The up panel shows APC/C 
controls several process including genomic integrity, apoptosis, autophagy, senescence, metabolism, stem cell and neuron regulation. In genomic 
integrity regulation part, genotoxic stress induced APC/C–Cdh1 activation and subsequently ubiquitylates substrates Rad17, Claspin and USP1 to 
regulate cell cycle checkpoint and recovery. In senescence process, APC/C–Cdh1 is activated by CDC14B and p21 to ubiquitylate substrates G9a 
and GLP and subsequently provokes IL-6 and IL-8 transcription. In apoptosis panel, Cdh1 targets MOAP1/Bax and Cdc20 targets Mcl1 and Bim1 to 
control apoptosis process. In metabolism regulation, APC/C–Cdh1 targets PFKFB3 and GLS1 to control glycolysis and glutaminolysis. In neuron, 
APC/C–Cdh1-mediates degradation of fragile X syndrome protein (FMRP), CK1δ, GluR1, Liprin-α, and Pfkfb3, APC/C–Cdc20 mediates ubiquitylation 
of Id2 and SnoN. In Stem cell, APC/C–Cdc20 mediates degradation of p21 and regulates pluripotency-related transcription factor SOX2 protein 
transcription activity. The down panel shows how APC/C potential controls autophagy process. APC/C–Cdh1-mediates degradation of PFKFB3, a 
critical factor in glucose metabolism and induces autophagy. Loss of PTEN, reduces APC/C–Cdh1-mediated degradation of PFKFB3, lead to strong 
inhibition of autophagy. On the other hand, APC/C–Cdh1 mediated chromatin accumulated PTEN degradation during mitotic exit
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Senescence is a stage when growth has been suspended 
and is a critical barrier for tumors in vivo and it is well 
known that the DNA damage response machinery plays 
a crucial role in executing these specific phenotypes. 
Recently studies revealed the APC/C could control the 
senescence process. Takahashi et al. reported that DNA 
damage provokes primary Lys 9 of histone H3 mono- 
(H3K9me1) and demethylation (H3K9me2) transferases 
G9a and GLP degradation via APC/C–CDH1 that acti-
vated via Cdc14B- and p21Waf1/Cip1 [90]. The decrease 
of G9a and GLP lead to reduce H3K9me1/2 driving the 
transcription of senescence-associated secretory pheno-
type (SASP) interleukins IL-6 and IL-8 in senescent cells. 
Therefore, the APC/C–Cdh1–G9a/GLP signals axis links 
the DNA damage response (DDR) and SASP responses in 
senescent cells. Johmura et al. found that normal human 
diploid fibroblasts (HDFs) that were influenced by stimuli 
to bring about senescence interestingly underwent a skip 
in events of mitosis before entry permanent cell-cycle 
arrest which is mediated by p53 activation of APC/C–
Cdh1 and pRb [111]. Activation of p53/p21 at G2 phase 
results in the impulsive activation of APC/C–Cdh1 that 
destroys various mitotic regulators, subsequently leading 
a switch in roles of Cdt1 and inducing senescence.
APC/C in autophagy
One of the newest findings in recent years is the con-
nection between APC/C with autophagy. Autophagy 
is a natural regulated degrading mechanism that regu-
lated the coordinated degradation and recycling of cel-
lular compounds [112]. During the events of autophagy, 
it is well known that autophagosomes are created which 
then subsequently fuse with a lysosomal organ and the 
internal components are then degraded via lysosomal 
enzymes. Autophagy has been implicated as a mecha-
nistic consequence of stress promoting cell survival, 
however in different scenarios, it has been shown to pro-
mote cell death [112]. Studies have shown the associa-
tion of APC and Cdh1 plays important role in regulating 
autophagic process bifunctional 6-phosphofructo-2-ki-
nase/fructose-2,6-bisphosphatases (PFKFBs) controls 
glycolysis by regulating the levels of fructose 2,6 bis-
phosphate (F2,6BP), a critical activator of phosphofruc-
tokinase 1 (PFK-1). The PFKFB family comprise four 
isoforms of which PFKFB3 is of specific concern to the 
pharmaceutical industry since PFKFB3 mRNA has been 
shown to be elevated in certain tumors. Recently study 
demonstrated loss of PTEN, a well-known tumor sup-
pressor, reduces stabilization of PFKFB3 by enhancing 
APC/C–Cdh1-mediated degradation [113]. Inhibition 
of the PFKFB3 decreases cancer cell glucose metabolism 
and induces autophagy [114, 115]. This consists with the 
reports that loss of PTEN, causes the strong inhibition of 
autophagy [116–118]. On the other hand, phosphoryl-
ated PTEN by PLK1 accumulates on chromatin during 
mitosis, and the APC/C–Cdh1 facilitate removal of chro-
matin-bound PTEN, which is a critical step for mitotic 
exit [119, 120]. In addition, in response to stress result-
ing from protein damage, APC/C is responsible for the 
ubiquitination and subsequent degradation of heat shock 
factor 2 (HSF2). HSF1 and HSF2 are transcription factors 
contributing expression of heat shock proteins (Hsps) by 
directly binding to the Hsp70 promoter in response to 
stress [121]. HSF2 was also suggested induce autophagic 
cell death upon heat shock [122]. This indicated the 
APC/C–Cdh1 could be a critical regulator in autophagy 
onset by degrading PFKFB3 and HSF2. While the reports 
on the observation of APC/C in regulating autophagy is 
still increasing, the detailed mechanism by which how 
APC/C is recruited to modulate the process of autophagy 
and its working mechanisms both in vitro and in vivo are 
needed to be addressed carefully.
In addition to APC/C potential control autophagy 
process, autophagy could in reverse regulate APC/C 
activity. Dotiwala et  al. reported that in budding yeast 
hyperactivation autophagy induced by DNA damage, 
causes nuclear exclusion of both esp1/separase and Pds1/
securin, which counteract the nuclear degradation of 
Pds1 by APC/C, and leads to a permanent G2/M arrest 
of cell [123]. Glucose withdrawal can decrease levels of 
ATP which then subsequently begin an autophagy cas-
cade to increase levels of ATP via lysosomal degradation 
[124, 125]. The APC/C activation also depends on the 
hydrolysable ATP and needs chaperone ATPase such as 
HSP70 and HSP90 [126, 127]. Recent studies revealed 
that HSP70 inhibitor PES-Cl inhibit both autophagy and 
the activity of APC/C and lead to cell cycle arrest, which 
indicates HSP70 may bridge the autophagy and APC/C 
activity regulation [128].
APC/C in metabolism
Emerging observation in has implicated APC/C in regu-
lating cellular metabolism. In brain energy metabolism, 
cortical neurons actually have a decreased capacity to 
utilize glucose via glycolysis compared to the metabolism 
of astrocytes, instead they utilize glucose to maintain 
regulated levels of antioxidants via APC/C–Cdh1/Pfkfb3 
[129]. PFKFB3, which is a rate-limiting regulator of gly-
colysis through the generation of fructose-2,6-bisphos-
phate (F2,6BP), was initially reported to be degraded by 
APC/C–Cdh1 in neurons [130]. In astrocytes, PFKFB3 is 
constantly existent due to low APC/C–Cdh1 activity, but 
in neurons, the PFKFB3 is absent that it is always subject 
to proteasomal degradation by APC/C–Cdh1. In brain 
energy metabolism, APC/C–Cdh1 activity is repressed 
by over-activation of glutamate receptors NMDAR 
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(N-methyl-d-aspartate subtype of glutamate recep-
tors) through Ca2+-Cdk5-dependent signaling pathway 
which leads to Cdh1 phosphorylation [131]. Activation 
of NMDAR by glutamate analog NMDA caused PFKFB3 
stabilization leading to increased glycolysis and reduced 
action of the pentose-phosphate pathway (PPP) which 
triggered oxidative stress and resulting neuronal death 
by excitotoxicity. Therefore, targeting the NMDAR-
APC/C–Cdh1/PFKFB3 protein regulation cascade which 
controlling brain energy metabolism is potential a novel 
therapeutic strategy for neurodegenerative diseases.
It has demonstrated that metabolism and cell cycle 
progression are integrated and coupled with each other. 
The initiation step of metabolic machinery adaptation 
includes Glycolysis and glutaminolysis. In the process of 
cellular division, the activation of glycolysis and glutami-
nolysis are strict via the effects of two ubiquitin ligases, 
APC/C–Cdh1 and SCFβ-TrCP which regulate the stabiliza-
tion and activity of PFKFB3 and Glutaminase 1 (GLS1) 
[132]. Colombo et al. [133] report that the diminishing in 
APC/C–Cdh1 activity that occurs in late G1 phase leads 
to the accumulation of PFKFB3 and GLS1, and, subse-
quently, raised glycolysis and glutaminolysis to frustrate 
the restrictive checkpoint of the G1 phase by keeping 
up elevated amounts of glycolytic and glutaminolytic 
intermediates. These studies are consistent with previ-
ous finding that overexpression of Cdh1 largely averts 
the increase in glycolysis and glutaminolysis and reduces 
S phase cells proportion [134]. Interestingly the levels of 
PFKFB3 and GLS1 both are already low expression in 
G2 phase, when APC/C–Cdh1 is still inactive, implying 
the involvement of extra regulatory mechanisms, which 
subsequently shows how this restructuring of regulatory 
machinery is crucial to cellular proliferation.
APC/C in stem cells
Maintenance of stem cell self-renewal and regulation of 
stem cell terminal differentiation are critically correlated 
with cell-cycle control that orchestrates tissue specifica-
tion, organ homeostasis, and potentially tumorigenesis 
[135]. As a master mitotic regulator, APC/C is supposed 
to have an essential role in regulating the self-renewal 
and differentiation of stem cells. In drosophila, the 
Cdc20/fizzy (fzy) has been suggested to suppress cata-
strophic cellular stress induced necrosis in neural stem 
cells [136]. Loss of Cdc20/fizzy in neuroblasts showing 
reduced APC/C activity resulting necrosis, by contrast, 
the gain of non-degradable type of APC/C substrates 
required for cell cycle progression leads to mitotic defect. 
Mao et  al. [137] reported that APC/C–Cdc20 controls 
human glioblastoma stem-like cells (GSCs) invasion and 
self-renewal, and its tumorigenicity in  vivo. APC/C–
Cdc20 interacts with and regulates pluripotency-related 
transcription factor SOX2 protein transcription activity 
but not degradation and results driving GSC invasive-
ness and self-renewal. During prometaphase, APC/C–
Cdc20 mediating the degradation of p21 leads to full 
activate CDK1 and prevents mitotic slippage [138]. Xie 
et  al. [139] reported that APC/C–Cdc20, which is tran-
scriptionally controlled by Forkhead transcription fac-
tor M1 (FoxM1), maintains tumor initiating cells (TICs) 
through degradation of p21CIP1/WAF1, a critical nega-
tive regulator of TICs in glioblastoma. FoxM1 activity is 
needed for the appropriate expression of different types 
of controller of mitosis, such as Cyclin B, Plk1, Aurora B 
and Cdc25B [140]. Interestingly, the foxM1 is also a sub-
strate of APC/C–Cdh1 [101, 141]. FoxM1 is degraded at 
mitotic exit by APC/C–Cdh1 and its degradation is criti-
cal for regulated entry into S phase. Therefore, APC/C–
Cdh1 may have different role in tumor initiating cells 
regulation.
In embryonic stem cells (ESCs), the cell cycle features 
show comparative S phase to somatic cells but have unu-
sually shorter G1 and G2 phase [142]. The APC/C sub-
strates such as Aurora A, Cdh1, Cdt1, Cyclin A, Cyclin 
B, Geminin, Plk1, and Securin decrease significantly after 
mitotic exit, but the degradation of the substrates is not 
as significant as that seen in somatic cells [143]. APC/C–
Cdh1 is inactive in undifferentiated ESCs but do become 
active as levels of inhibitors of Emi1 decrease [144]. Also 
unlike somatic cells, in the G1 and S phases it has been 
shown that Cdc20 is present but dissociates from APC/C 
of ESCs cells [143]. Mice with no Cdc20 function proved 
to be embryologically fatal due to cell cycle arrest in met-
aphase at the two-cell stage with high levels of cyclin B1 
[145].
APC/C in neuron
Accumulating evidence suggests that APC/C is critical 
in regulating neuron development and neuronal func-
tion via governing the turnover of some neuron-specific 
proteins. Specifically, APC/C–Cdh1 was found to con-
trol axon growth and patterning in the process of normal 
brain development [146]. Subsequent studies reported 
that mechanistically, APC/C–Cdh1 regulates neuronal 
development through targeting two axon growth-pro-
moting factors, Id2 and SnoN, for degradation [147, 
148]. Subsequent studies revealed that APC/C–Cdc20 
regulates dendrite morphogenesis and presynaptic dif-
ferentiation through degradation of the transcription 
factors Id1 and NeuroD2 [149, 150]. Further studies 
showed that synaptic plasticity, synaptic size and the 
bioenergetics and antioxidant status of neurons are con-
trolled by APC/C–Cdh1 mediated degradation of GluR1 
[151], Liprin-α [152, 153] and Pfkfb3 [113]. Recently 
studies revealed APC/C–Cdh1 driving the hippocampal 
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mGluR-dependent synaptic plasticity in the mammalian 
brain through degrade the fragile X syndrome protein 
(FMRP) [154]. APC/C–Cdh1 targets CK1δ for degrada-
tion which regulates cerebellar granule cell neurogen-
esis [155]. Although several aspects of how the APC/C 
regulates the nervous system have been uncovered at the 
cellular level, it remains largely unclear how at the organ-
ismal level, APC/C deficiency could affect neuronal func-
tion, including mammalian learning and memory [156], 
and whether APC/C functions in neurological and psy-
chiatric disorders.
APC/C in tumorigenesis
Most of APC/C regulated cellular functions are directly 
or indirectly connected to tumor initiation or inva-
sion. Results from pathological studies unveiled a series 
of mutations in ANAPC3/Apc3, ANAPC6/Apc6, and 
ANAPC8/Apc8 in breast cancer, colon cancer, glioma, 
hepatocarcinoma, melanoma, neuroblastoma, chorio-
carcinoma tissues [157]. Further results based on mouse 
targeting deletion or xenograft studies demonstrated that 
APC/C coactivator Cdc20 or Cdh1 to be as oncoprotein 
or tumor suppressor in many types of cancer [83].
Recently, some studies have shown that increased 
Cdc20 expression is concomitant with clinical progres-
sion in various types of human tumors which consistent 
with the notion that Cdc20 may have functions simi-
lar to many oncoproteins. For example, high expression 
of Cdc20 was observed in primary non-small cell lung 
cancer (NSCLC) patients [158], colorectal cancer [159]. 
Moreover, Cdc20 expression was positively correlated 
with clinicopathological parameters including invasion, 
and pathological tumor status. In genetic mouse model, 
mouse loss of Cdc20 is embryonic lethality at the two-cell 
stage because of metaphase arrest [145]. Further studies 
revealed APC/C cofactor Cdc20 is crucial for anaphase 
onset in  vivo in both embryonic cells and somatic cells 
including progenitor cells [160]. In a tamoxifen induc-
ible conditional Cdc20 knockout mouse (Cdc20−/lox/
RERT+/Cre) chemical induced skin cancer model, abla-
tion of Cdc20 results in Cdc20 ablation can subsequently 
result in complete tumor regression in  vivo via apopto-
sis. Further histological analysis revealed that depletion 
of Cdc20 in skin tumors resulted in tumor cell arrest in 
metaphase, accompanied by induction of cellular apopto-
sis [160].
Cdh1, an APC/C cofactor is a well-known tumor sup-
pressor [161]. Through studies it has been shown that 
inhibition of Cdh1 can lead to centrosome amplifica-
tion and incorrect chromosome segregation, and thus 
has been associated with genetic instability and tumo-
rigenesis, Cdh1 deficient (Fzr1+/−) mice develop sev-
eral types of epithelial tumors, such as fibroadenomas 
and mammary gland adenocarcinomas, which are not 
observed in Cdh1 wild-type (Fzr1+/+) mice [91]. Nota-
bly, Cdh1 expression has been shown to be decreased in 
ovary, prostate, breast, colon, brain and liver tumor cell 
lines [75, 108, 162, 163]. Concomitant with downregula-
tion of Cdh1 expression, several APC/C–Cdh1 targets, 
such as Aurora A, Aurora B, Cdc6, Cdc20, Cyclin B, 
Rad17 and Tpx2 are often upregulated in human cancer 
tissue samples [164]. On the other hand, Lehman et  al. 
demonstrated that Cdh1 was overexpressed in certain 
tumor types [165].
APC/C and drug development
Given the pivotal role of APC–Cdc20 in governing 
mitotic progression, blockade of chromatid segregation 
or mitotic exit largely attracts the attention for develop-
ment of small molecule inhibitor that could be utilized 
to suppress cancer cell growth or induce cancer death. In 
recent studies, it was shown that a relevant target might 
be mitotic exit because it the pro-apoptotic consequences 
of RNAi against the APC/C cofactor, Cdc20 [166]. Sev-
eral APC/C inhibitors have been developed recent years, 
such as pro-TAME [167], Apcin [168] (Fig. 6). The pro-
TAME disrupts APC3–Cdc20 IR-tail binding interaction 
but in this case, Cdc20 can still be enlisted to the APC/C 
via the interactions between its C-box and co-receptors. 
TAME discharges Cdc20 from the APC/C by boosting 
Cdc20 auto-ubiquitination and subsequent Cyclin B1 sta-
bilization [169]. It was also shown that Cyclin B1 counter-
acts TAME’s effect by boosting recruiting of free Cdc20 
to the APC/C, meanwhile, Cdc20 autoubiquitination 
is also decreased. Most recently, Sackton et  al. revealed 
combined use of Apcin, which disrupts D-box interaction 
between Cdc20 and the substrate, and TAME jointly dis-
rupt the interface between APC/C, Cdc20 and substrate 
and thereby having the combined effect of increasing the 
duration of mitosis and blocking its exit [168].
It has also been shown that use of anti-mitotic drugs 
could prove to be lethal with the use of chemical drugs. 
Giovinazzi et  al. also reported proTAME prohib-
ited mitotic exit of paclitaxel and Aurora A inhibitor 
MLN8054 arrested cells induced apoptosis [170]. Eguren 
et  al. reported that loss of Cdh1 results in an increased 
sensitivity to DNA topoisomerase 2-alpha (Top2α) inhib-
itors such as etoposide and ICRF-193 as an outcome of 
augmented amount of Top2-DNA trapped complexes 
[171]. It is also worth noting that in cancer cells inhibi-
tion of APC/C by chemical inhibitor pro-TAME could 
sensitize Top2α inhibitors. While the results of valida-
tion of the above inhibitors based on cultured-cell and 
xenograft models shed light on novel anti-cancer strat-
egy, preclinical study with combination to various chemo 
drugs in different patient-derived xenograft models will 
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further validate and enhance the potential of APC inhibi-
tors in future’s anti-cancer treatment.
Conclusion and future direction
Although APC/C was initially characterized to be a 
master regulator of cell cycle control, results from over 
decade uncovered its feature as a multiple functional 
ubiquitin protein ligases. Demonstration of its participa-
tion in various types of cellular processes, environmen-
tal stress as well as communication between pathogen/
host largely implicates its impact in the maintenance of 
homeostasis and otherwise diseases. Recently years’ pro-
gress in 3D structural studies and different types of ubiq-
uitin chains catalyzed by APC/C significantly enhance 
the in-depth view about how the APC/C works and its 
regulation. Development of its small molecule inhibi-
tors shed light on its potential value in anti-cancer treat-
ment and other diseases. While novel function of APC/C 
is linked to regulation of cellular metabolism, emerging 
evidence has also sketched the previous undocumented 
role to autophagy. Despite the exciting new findings for 
APC/C, following future efforts could further enhance 
our understanding of APC/C and promote its transla-
tional value in anti-cancer treatment. Current 3D struc-
tural work from Barford and other laboratories provides 
much clear and accurate topological picture for APC/C 
subunits as well as the activators, which allows a better 
designing of more potent small molecule modulators for 
chemical genetic study and drug development. Informa-
tion based on the findings of various types of chains cata-
lyzed by APC/C would encourage more detailed work 
from the view of physiology, which could validate the 
relevance of fine-tuning from the level of ubiquitin chain 
formation. Biochemically, how exactly the large com-
plex of APC/C is assembled still remains unclear. Some 
recent results based on mass spectrometry analyses sug-
gest that one functional protein could be simultaneously 
regulated by multiple-types of posttranslational modi-
fications in order to achieve certain physiological effect. 
Thus, if APC/C-mediated ubiquitylation interplays with 
Fig. 6 APC/C in tumorigenesis and drug development. Currently, Cdc20 has been recognized as tumor enhancer, whereas Cdh1 has been recog-
nized as tumor suppressor in most type of cancer. Developing specific APC/C inhibitors are potential therapeutic target for cancer treatment. Two 
inhibitors have been developed, the pro-TAME disrupt APC3-Cdc20 IR-tail binding and Apcin inhibit the D-box binding between Cdc20 and the 
substrate. The pro-TAME and Apcin have synergistic blockade of mitotic exit effect due to different APC/C activity disrupt mechanism
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other posttranslational modification in orchestrating 
substrate protein in response to signaling or stress needs 
to be considered. Beyond cell cycle control, if APC/C-
mediated catalysis needs entire 15 subunits or whether 
smaller complex with necessary subunits could satisfy 
the commitment for APC/C under various physiological 
circumstances is unknown. Several deubiquitinases were 
reported to be involved in APC/C governed regulation 
by counteracting its ubiquitylation. Given the large list 
of APC/C substrates, if certain deubiquitinases could be 
shared by different APC/C regulated substrates remain 
unknown. It’s now clear that APC/C has a critical respon-
sibility in cell division, stem cell regulation, neuronal pro-
cesses, cell death and tumorigenesis. Besides the basic 
research, it is anticipated that further validation of newly 
developed APC/C small molecule inhibitors by utilizing 
various animal disease models would lead to a new era 
for APC/C.
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